Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment

    Not Recruiting
  • End date
    Dec 1, 2022
  • participants needed
  • sponsor
    Intercept Pharmaceuticals
Updated on 12 May 2021
Judith Romano
Primary Contact
Universitatsklinikum Leipzig AoR (0.9 mi away) Contact
+46 other location
platelet count
liver disease
acute liver failure
liver failure
obeticholic acid
antimitochondrial antibody
glutaric acid


This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the PK and safety of OCA treatment in patients with primary biliary cholangitis (PBC) and moderate to severe hepatic impairment over a 48 week treatment period. Patients who have completed their 48-week double blind treatment period will continue double-blind treatment until all randomized patients have completed their 48-week treatment period and the database for that period is locked. An open-label extension study in which all patients receive OCA will be considered following review of blinded safety and PK data.

Condition Primary biliary cirrhosis, Primary Biliary Cholangitis
Treatment Placebo, Obeticholic Acid (OCA)
Clinical Study IdentifierNCT03633227
SponsorIntercept Pharmaceuticals
Last Modified on12 May 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note